Bayer/Onyx Submit NDA For Kidney Cancer Agent BAY 43-9006
This article was originally published in The Pink Sheet Daily
Executive Summary
Bayer and Onyx expect to launch their multi-targeted renal cell carcinoma therapy BAY 43-9006 (sorafenib) in early 2006. The companies completed NDA submission for the kidney cancer drug based on interim Phase III results; the study is continuing to track survival.